MSD and the European Organisation for Research and Treatment of Cancer (EORTC) have released new data showing that the anti-PD-1 therapy Keytruda significantly prolonged recurrence-free survival (RFS) in patients with high-risk stage III melanoma.
News
Shire sells oncology unit to Servier for $2.4bn
Dublin, Ireland-based Shire is selling its oncology unit to France’s Servier in a deal worth $2.4 billion.
MPs criticise NHS Digital/Home Office data sharing deal
The Health and Social Care Committee has voiced “serious concerns” about NHS Digital’s ability to protect patient data, after reviewing its Memorandum of Understanding with the Home Office that allows data sharing to trace immigration offenders.
Seats filling up fast at International Clinical Researcher of the Year
Get yours now before it’s too late!
UK study to investigate kidney disease progression
A large-scale observational study of chronic kidney disease (CKD) is due to launch in general practices this month, involving 3,205 Oxfordshire residents and led by Oxford University researchers.
Public backs tax rise for NHS
A new analysis has revealed growing concern among the public over the financial state of the NHS, and support for raising taxes to help ensure that the service remains free at the point of use.
NHS in “never-ending winter”
Warning bells for the NHS are ringing again after the latest performance data showed the highest number of emergency admissions since records began and more patients than ever before waiting more than four hours for treatment.
UCB and PharmaMar breach ABPI Code of Practice
UCB and PharmaMar have been named in advertisements for breaching the Association of the British Pharmaceutical Industry’s Code of Practice.
UK’s Enterprise Therapeutics raises £29m
Brighton, UK-based Enterprise Therapeutics has raised £29 million to help it advance its experimental therapies for respiratory diseases.
GSK hands rare disease gene therapies over to Orchard
Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies.
Pfizer pulls plug on Inlyta trial
Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
US delay for AbbVie/Neurocrine’s uterine pain drug
The US Food and Drug Administration has extended its review of AbbVie and Neurocrine’s experimental uterine pain drug elagolix by three months.
Final guidance from NICE on Merck, Pfizer’s Bavencio
The National Institute for Health and Care Excellence has now published final guidelines endorsing Merck and Pfizer’s Bavencio as an option for patients with Merkel cell carcinoma (MCC).
Novartis’ Afinitor Disperz wins new TSC-related approval
Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
Alexion to buy Wilson for $855m
Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million.
